Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (November 2018)
25 slides from Nova Eye Medical's shareholder meeting presentation, Nov 28, 2018
Slide 1: Ellex Medical Lasers Limited Presentation to Annual General Meeting
Ellex Medical Lasers Limited (ASX:ELX) Presentation to Annual General Meeting 28 NOVEMBER 2018 ADELAIDE, AUSTRALIA
Slide 2: Disclaimer
2 2018 ANNUAL GENERAL MEETING Disclaimer This presentation has been prepared by Ellex Medical (Ellex, ELX: ASX). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequac
Slide 3: Contents
3 2018 ANNUAL GENERAL MEETING Contents 1. Our Business 2. Our Strategies 3. FY18 Operating Highlights 4. FY18 Financial Results 5. 2RT LEAD Clinical Study Results & Next Steps 6. FY19 Trading Update 7. Outlook
Slide 4: Our Business
4 2018 ANNUAL GENERAL MEETING Our Business Today, over 35,000 Ellex ophthalmic laser and ultrasound systems are in use around the globe; and we have sold over 20,000 consumable devices to treat patients with glaucoma • Our network of over 50 distributors in over 100 countries provides us with an abi
Slide 5: Our Business
5 2018 ANNUAL GENERAL MEETING Our Business 82m people worldwide 107m people worldwide with glaucoma with diabetic retinal disease Retinal Glaucoma Disease US $4.6bn US $1.9bn AMD Cataract 122m people with US $5.1bn US $3.3bn 25.3m early age-related cataract operations macular degeneration performed
Slide 6: Our Strategies
6 2018 ANNUAL GENERAL MEETING Our Strategies 1. Ellex Laser & Ultrasound: we will continue to provide a strong base for our business using our well-known industry heritage and strong market position through a combination of technological innovation, new product releases, marketing and cost managemen
Slide 7: Our Strategies - Glaucoma
7 2018 ANNUAL GENERAL MEETING Our Strategies - Glaucoma Ellex is the only ophthalmic company globally with products to treat across the full spectrum of the glaucoma disease process. EARLY INTERMEDIATE LATE LASER MIGS* SURGERY Treating both Angle Closure and primary open angle glaucoma MEDICATION AS
Slide 8: Our Strategies - Glaucoma
8 2018 ANNUAL GENERAL MEETING Our Strategies - Glaucoma • Two major trends driving growth in Ellex glaucoma products: (1) Market shift from eye drops to SLT (laser) treatment in early patients and (2) Widespread adoption of MIGS • Glaucoma market expected to grow from US$4.9bn to US$5.3bn in 2022, d
Slide 9: Our Strategies – AMD
9 2018 ANNUAL GENERAL MEETING Our Strategies – AMD Ellex is the only ophthalmic company globally with a laser-based intervention in intermediate AMD (iAMD) which has shown clinical efficacy in a large, randomized controlled clinical study, the LEAD study. AMD EARLY STAGE No approved Progression over
Slide 10: 2RT intervention to prevent blindness
Our Strategies – AMD 2RT® intervention to prevent blindness Morbidity Health of retina and macula Normal Vision AMD progression without Ellex 2RT® 2RT® slows AMD progression by 77% 2RT® application Defer CNV / GA Visual difficulty GA with vision loss, or CNV requiring anti- VEGF injection Blindness
Slide 11: Our Strategies - AMD
11 2018 ANNUAL GENERAL MEETING Our Strategies - AMD 1. Our short term strategy is to increase our ELLEX 2RT® LASER European, Australian and NZ footprint, where Ellex 2RT® is approved for iAMD (leveraging LEAD) 2. Our medium term strategy (<12 months) is to identify a pathway from the FDA for registr
Slide 12: FY18 Operating Highlights
12 2018 ANNUAL GENERAL MEETING FY18 Operating Highlights • Expanded China footprint for Ellex iTrack ™ - only approved MIGS • Raised $23.6M in additional capital from share placement & SPP • Major expansion of Ellex iTrack™ sales and marketing in the USA & other markets • Increased production capaci
Slide 13: FY18 Financial Results
13 2018 ANNUAL GENERAL MEETING FY18 Financial Results Constant currency (cc)1 sales growth of 13% to $79.1M compared to prior corresponding period (pcp), driven by: $4M improvement in • 39% cc growth in Ellex iTrack ™ sales to $11.4M operating cash flow to (incl. 48% growth in USA) $0.5M versus pcp
Slide 14: FY18 Financial Results – Ellex iTrack
14 2018 ANNUAL GENERAL MEETING FY18 Financial Results – Ellex iTrack™ Strong performance at the unit 12 months to 30 June in US$ level, with 31% growth versus pcp 2017 2018 Growth Units: • Revenue growth in US$ outpaced volumes USA 4,347 6,392 47% due to beneficial mix effects (higher China 1,165 1,
Slide 15: FY18 Financial Results – Ellex iTrack
15 2018 ANNUAL GENERAL MEETING FY18 Financial Results – Ellex iTrack™ Strong growth in re-orders from US clinicians, highlighting greater adoption and throughput at the centre level • New account orders comprise 15% of ELLEX iTRACK™ USA SALES REVENUE mix (compared to 9% FY17) 3,000,000 • 39% growth
Slide 16: FY18 Financial Results – Lasers & Ultrasound
16 2018 ANNUAL GENERAL MEETING FY18 Financial Results – Lasers & Ultrasound Segment revenue CAGR over FY13-FY18 of 8% • Strong performance from Tango™ • Cataract and vitreous opacity ELLEX LASER & ULTRASOUND REVENUE BY DISEASE (A$) and Tango Reflex™ SLT lasers to laser sales declined 16% to treat gl
Slide 17: 2RT for Intermediate AMD
17 2018 ANNUAL GENERAL MEETING 2RT® for Intermediate AMD • Ellex released the LEAD clinical results in September 2018 • LEAD was the first ever study to show a significant efficacy effect in an iAMD population 76% of patients • Over three-quarters of patients treated every six months exhibited a 77%
Slide 18: Presentation of LEAD Study
18 2018 ANNUAL GENERAL MEETING Presentation of LEAD Study Significant physician education and marketing campaign at AAO, Chicago (~25,000 attendees) and EURETINA, Vienna (~5,000 attendees) • Hosted an AAO Roundtable with experts in AMD to generate enduring educational content for clinicians Prof. An
Slide 19: Presentation of LEAD Study
19 2018 ANNUAL GENERAL MEETING Presentation of LEAD Study Major focus on practice development via patient education and referral tools • Online tools to capture significant patient traffic i.e. www. Retinal-Rejuvenation.com
Slide 20: 2RT Next Steps – EU, AUS, NZ
20 2018 ANNUAL GENERAL MEETING 2RT® Next Steps – EU, AUS, NZ • Since 2014, Ellex has European (CE Mark) clearance for 2RT® in the treatment of early AMD • Limited installed base in Europe, as clinicians were waiting for LEAD data • Since LEAD, our strategies in these three markets have focused on: •
Slide 21: 2RT Next Steps - USA
21 2018 ANNUAL GENERAL MEETING 2RT® Next Steps - USA • Ellex 2RT® has clearance for 2RT® in Clinically Significant Macular Edema (CSME), but not iAMD • To allow Ellex to promote and sell 2RT® on-label in the USA for iAMD requires an additional claim on its approved label (to include iAMD) • Prioriti
Slide 22: FY19 Trading Update
22 2018 ANNUAL GENERAL MEETING FY19 Trading Update • 4 month group sales to 31 October have increased 27% to $24.7M [17% on constant currency (cc)1] • Sales growth driven by key glaucoma franchise comprising Ellex iTrack ™ and SLT laser portfolio (Ellex Tango ™ / Ellex Tango Reflex ™ ) • Ellex iTrac
Slide 23: Outlook
23 2018 ANNUAL GENERAL MEETING Outlook Ellex remains on track to grow group sales and deliver an improved operating result in FY19 subject to global economic conditions and foreign exchange rates • Multi-product glaucoma segment will remain the primary driver of sales growth in FY19 • Ellex iTrack ™
Slide 24: Contacts
24 2018 ANNUAL GENERAL MEETING Contacts TOM SPURLING MARIA MAIELI DR. TOM DUTHY CEO CFO & Investor Relations & Company Secretary Corporate Development M (USA) : +1 510 504 1267 M (AUS) : +61 417 818 658 W: +61 8 7074 8200 M: +61 402 493 727 E: tspurling@ellex.com E: mmaieli@ellex.com E: tduthy@ellex
Slide 25: Questions/Discussion
25 2018 ANNUAL GENERAL MEETING QUESTIONS/DISCUSSION
Nova Eye Medical — Shareholder Meeting (November 2018) on 6ix